First-line cemiplimab significantly improved overall survival (OS) and progression-free survival (PFS) in patients with advanced NSCLC* with PD-L1** tumour expression of ≥50 percent, according to the EMPOWER-Lung 1*** study presented at ESMO 2020.
Surufatinib, a novel small-molecule inhibitor that targets tumour angiogenesis and immune evasion, improves progression-free survival (PFS) in patients with progressive, advanced, well-differentiated pancreatic neuroendocrine tumours (pNETs), according to results of the SANET-p trial presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
In patients with stage IB–IIIA EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) who have undergone complete tumour resection, adjuvant osimertinib significantly reduces the risk of recurrence, including in the central nervous system (CNS), results of an exploratory analysis of the phase III ADAURA trial have shown.
Individualized starting dose (ISD) of maintenance niraparib improves progression-free survival (PFS) vs placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), results of the NORA trial have shown.
Pembrolizumab in combination with chemotherapy significantly improves overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) vs chemotherapy alone in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer, according to results of the phase III KEYNOTE-590 study presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
The PD-1 inhibitor nivolumab continues to yield sustained recurrence-free survival (RFS) benefit over ipilimumab with better tolerability at 4 years in the adjuvant setting for patients with resected stage IIIB–C or IV melanoma, according to the CheckMate238 trial presented at ESMO 2020.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.